口服JAK抑制剂治疗白癜风的真实世界疗效与安全性:回顾性研究
该单中心回顾性研究纳入96例接受口服JAK抑制剂至少3个月的白癜风患者,评估真实世界疗效与安全性。结果显示总应答率为55.2%,显著复色率(≥76%)为9.4%,年龄、光疗史和用药超过6个月是应答的独立预测因素,未观察到严重不良事件。
要点
- 口服JAK抑制剂治疗白癜风总应答率55.2%,显著复色率9.4%
- 用药超过6个月与更好的治疗应答独立相关
- 年龄和光疗史也是JAK抑制剂应答的独立预测因素
核心结论
- 口服JAK抑制剂对白癜风患者有效且安全,用药超过6个月者结局优于短期用药者。
研究设计与样本
- 单中心回顾性研究,纳入96例接受口服JAK抑制剂至少3个月的白癜风患者。
- 总应答率定义为达到>25%复色的患者总百分比。
- 采用多变量逻辑回归分析识别应答和口服JAK抑制剂的预测因素。
主要发现
- 96例患者中86例(89.6%)达到不同程度的复色。
- 总应答率为55.2%,显著复色率(≥76%)为9.4%。
- 年龄、光疗史和口服JAK抑制剂用药超过6个月是应答的独立预测因素。
- 未观察到严重不良事件。
临床怎么用
- 口服JAK抑制剂可作为白癜风治疗的有效选择,建议持续用药超过6个月以获更好结局。
- 年龄、光疗史和用药时长可用于预判JAK抑制剂治疗应答。
局限性
- 单中心研究,患者数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing numbers of studies have demonstrated that oral Janus kinase inhibitors (JAKis) are effective in the treatment of vitiligo. However, large-scale data on their effectiveness and safety remain limited. OBJECTIVE: We aimed to assess the effectiveness and safety of oral JAKi in vitiligo treatment and explore potential predictive factors associated with response to JAKi under real-world conditions. METHODS: A retrospective study was conducted in vitiligo patients who had received oral JAKi for at least 3 months. The overall response rate was the total percentage of patients who achieved >25% repigmentation. Multivariable logistic regression analysis identified predictors for response and oral JAKi. RESULTS: A total of 96 patients were included, 86 (89.6%) of whom achieved different degrees of repigmentation. The overall response rate was 55.2%, and the rate of marked repigmentation (≥76%) was 9.4%. Age, history of phototherapy, and oral JAKi administration for more than 6 months were independent predictors of response to JAKi. No severe adverse events were observed. LIMITATIONS: A single-center study with limited patients. CONCLUSION: Oral JAKi were effective and safe for patients with vitiligo. Patients taking oral JAKi for more than 6 months had better outcomes than those who received JAKi for a shorter period.
引用
- Shi X, Yuan Y, Sun R, et al. Real-world effectiveness and safety of oral Janus kinase inhibitor in vitiligo: A retrospective study. J Am Acad Dermatol. 2025. PMID: 40976534. doi:10.1016/j.jaad.2025.09.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。